Literature DB >> 1631600

Towards a new approach for estimating indirect costs of disease.

M A Koopmanschap1, B M van Ineveld.   

Abstract

Many researchers in the field of evaluation of health care doubt the usefulness of estimates of indirect costs of disease in setting priorities in health care. This paper attempts to meet part of the criticism on the concept of indirect costs, which are defined as the value of production lost to society due to disease. Thus far in cost of illness studies and cost-effectiveness analyses the potential indirect costs of disease were calculated. In the following a first step will be taken towards a new method for estimating indirect costs which are expected to be effectuated in reality: the friction cost method. This method explicitly takes into account short and long run processes in the economy which reduce the production losses substantially as compared with the potential losses. According to this method production losses will be confined to the period needed to replace a sick worker: the so called friction period. The length of this period and the resulting indirect costs depend on the situation on the labour market. Some preliminary results are presented for the indirect costs of the incidence of cardiovascular disease in the Netherlands for 1988, both for the friction costs and the potential costs. The proposed methodology for estimating indirect costs is promising, but needs further development. The consequences of illness in people without a paid job need to be incorporated in the analysis. Also the relation between internal labour reserves and costs of disease should be further investigated. Next to this, more refined labour market assumptions, allowing for diverging situations on different segments of the labour market are necessary.

Entities:  

Mesh:

Year:  1992        PMID: 1631600     DOI: 10.1016/0277-9536(92)90131-9

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  71 in total

1.  Household income losses associated with ischaemic heart disease for US employees.

Authors:  J Herrin; C B Cangialose; S J Boccuzzi; W S Weintraub; D J Ballard
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

2.  The Danish approach to standards for economic evaluation methodologies.

Authors:  A Alban; M Gyldmark; A V Pedersen; J Søgaard
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

3.  The role of cost-consequence analysis in healthcare decision-making.

Authors:  J A Mauskopf; J E Paul; D M Grant; A Stergachis
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

4.  Standardisation of costs: the Dutch Manual for Costing in economic evaluations.

Authors:  Jan B Oostenbrink; Marc A Koopmanschap; Frans F H Rutten
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 5.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  Does the EQ-5D reflect lost earnings?

Authors:  Carl Tilling; Marieke Krol; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

7.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

8.  Cost-of-illness studies: a major headache?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 9.  The relationship between productivity and health-related QOL: an exploration.

Authors:  Werner B F Brouwer; Willem-Jan Meerding; Leida M Lamers; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 10.  The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Authors:  Rachel Meacock; Nicola Dale; Mark J Harrison
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.